Vmbook Online ordering

Myriad Genetics Inc

Myriad Genetics, Inc. is a publicly traded company based in the United States that specializes in molecular diagnostics and genetic testing. The company's headquarters is located in Salt Lake City, Utah. Myriad Genetics' stock is listed on the NASDAQ stock exchange under the ticker symbol "MYGN".

Myriad Genetics was founded in 1991 and has since become a leader in the field of genetic testing, with a particular focus on hereditary cancer testing. The company's tests are used to identify genetic mutations that can increase an individual's risk of developing certain types of cancer, such as breast, ovarian, colon, and uterine cancer.

Myriad Genetics has developed and commercialized a number of proprietary genetic testing technologies, including BRACAnalysis, which is used to detect mutations in the BRCA1 and BRCA2 genes that are associated with an increased risk of hereditary breast and ovarian cancer. The company also offers a number of other genetic tests, including tests for hereditary colorectal cancer, hereditary high cholesterol, and hereditary thrombophilia.

Myriad Genetics has a strong financial position, with annual revenues of over $800 million and a market capitalization of several billion dollars. The company's financial performance has been driven by the growing demand for genetic testing, as well as the company's strong reputation for innovation and quality.

Overall, Myriad Genetics is a well-established and successful public company in the field of molecular diagnostics and genetic testing, with a strong track record of financial performance and innovation.